CS
Therapeutic Areas
Neumora Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Navacaprant (NMRA-140) | Major Depressive Disorder (MDD) | Phase 3 |
| NMRA-511 | Agitation in Alzheimer's Disease | Phase 1 |
| NMRA-266 (M4 PAM) | Schizophrenia | Preclinical |
Leadership Team at Neumora Therapeutics
HO
Henry O. Gosebruch
Chief Executive Officer
R(
Robert (Bob) Lenz, M.D., Ph.D.
Head of R&D and Chief Scientific Officer
JP
Joshua Pinto
Chief Financial Officer
PL
Paul L. Berns
Chairman of the Board
DA
Dimitri Azar, M.D., MBA
Chief Business Officer
JR
John R. Leonard, M.D.
Chief Medical Officer
MB
Muna Bhanji
Chief Corporate Affairs Officer
AD
Archana Dubey, M.D.
Director (Managing Partner, GV)
CF
Catherine Friedman
Director
T(
Terrence (Terry) C. Kearney
Director